XNCR News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

XN

Mkt Cap

$1.78B

Volume

974.25K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule TypeA comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.GlobeNewswire Inc. · Feb 18, 2026

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.GlobeNewswire Inc. · Jan 14, 2026

Xencor (XNCR) Q2 Revenue Jumps 82%Xencor reported strong Q2 2025 financial performance with revenue of $43.6 million, beating estimates by 93%. The company advanced several clinical programs in oncology and autoimmune disorders and received a significant milestone payment from Incyte.The Motley Fool · Aug 6, 2025

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.GlobeNewswire Inc. · Jul 16, 2025

Xencor Surges 10.5%: Is This an Indication of Further Gains?Xencor shares surged 10.5% after the company announced a secondary stock offering to raise $175 million. The company plans to use the funds to support its pipeline development. However, earnings and revenue expectations for the upcoming quarter are negative, which may impact the stock's future performance.Benzinga · Sep 12, 2024

Peeling Back The Layers: Exploring Xencor Through Analyst InsightsIn the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 2 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Sean McCutcheon Raymond James Lowers Strong Buy $40.00 $58.00 Etzer Darout BMO Capital Lowers Outperform $32.00 $34.00 Gregory Renza RBC Capital Lowers Outperform $31.00 $32.00 David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the ...Full story available on Benzinga.comBenzinga · Jun 14, 2024

Decoding 6 Analyst Evaluations For Xencor6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Xencor, presenting an average target of $33.0, a high estimate of $38.00, and a low estimate of $24.00. A decline of 17.91% from the prior average price target is evident in the current average. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Xencor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Edward Tenthoff Piper Sandler Lowers Neutral $24.00 $37.00 Gregory Renza RBC Capital Maintains Outperform $32.00 - Etzer Darout BMO Capital Lowers Outperform $34.00 $38.00 David Nierengarten Wedbush Lowers Outperform $34.00 $36.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of ...Full story available on Benzinga.comBenzinga · May 10, 2024

Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · May 6, 2024

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue EstimatesArdelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 2, 2024

Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.Zacks Investment Research · May 2, 2024

XN

XNCRXencor, Inc.

XNCR

Pay with—

Available Balance0.00

Your PositionYou don't own any XNCR yet.

Related Tickers

Earnings